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Short Telomeres are Sufficient to Cause the
Degenerative Defects Associated with Aging
Mary Armanios,1,* Jonathan K. Alder,1 Erin M. Parry,1,4 Baktiar Karim,2 Margaret A. Strong,3
and Carol W. Greider1,3
Telomerase function is critical for telomeremaintenance. Mutations in telomerase components lead to telomere shortening and progres-
sive bone marrow failure in the premature aging syndrome dyskeratosis congenita. Short telomeres are also acquired with aging, yet the
role that they play in mediating age-related disease is not fully known. We generated wild-type mice that have short telomeres. In these
mice, we identiﬁed hematopoietic and immune defects that resembled those present in dyskeratosis congenita patients. When mice
with short telomeres were interbred, telomere length was only incrementally restored, and even several generations later, wild-type
mice with short telomeres still displayed degenerative defects. Our ﬁndings implicate telomere length as a unique heritable trait that,
when short, is sufﬁcient to mediate the degenerative defects of aging, even when telomerase is wild-type.Introduction
Telomeres are DNA-protein structures that protect chro-
mosome ends. With cell replication, telomeres shorten
successively and ultimately lead to apoptosis or permanent
cell-cycle arrest. Telomeres have thus been long appreci-
ated as a determinant of replicative senescence in cells.1
With aging, telomeres also shorten in humans, yet their
role in mediating age-related disease is not fully known.
In the presence ofmutant telomerase components, short
telomeres cause a premature aging syndrome. In telomere-
mediated syndromes, short telomeres clinically manifest
as aplastic anemia in the bone marrow and progressive
ﬁbrosis in the lung and liver.2 Disease-associated muta-
tions in telomerase components were initially identiﬁed
in the context of dyskeratosis congenita (DKCX [MIM
305000]), a disorder characterized by early mortality due
to bone marrow failure.3,4 Loss-of-function mutations in
the essential components of telomerase, hTR, the telome-
rase RNA (MIM 602322), and hTERT, the catalytic reverse
transcriptase (MIM 187270), lead to telomerase haploin-
sufﬁciency and autosomal-dominant inheritance of dys-
keratosis congenita (DKCA [MIM 127550]).5,6 In families,
the organ failure displays anticipation, an earlier and more
severe onset with each generation, which is associated
with progressive telomere shortening.5,7 These observa-
tions have implicated telomere length as an important
modiﬁer of disease penetrance in families that carrymutant
telomerase genes. However, whether short telomeres alone,
in the absence of telomerase mutations, can mediate
disease with aging is not known.
Telomerase function is critical for organ homeostasis.
Hematopoietic stem cells and lymphocytes are enriched
for telomerase activity, suggesting that their self-renewal
potential may depend on the presence of telomerase.8,9The AmericanThis observation would imply that telomerase may protect
against degenerative defects in these compartments by
preventing telomere shortening. In approaching these
questions, the study of telomerase function in mammalian
models has relied on laboratory mouse strains that possess
long, heterogeneous telomere lengths that do not mimic
human telomere dynamics.10–13 Inmost laboratory strains,
the average telomere length is ~50–70 kb, compared with
the average human telomere length of ~10 kb.14 Therefore,
on these strains, end organ dysfunction is present only
when telomerase is null and after several generations
of breeding when telomeres are short. Late-generation
mTR/ mice have organ dysfunction that manifests as
a stem cell failure disorder and prominently affects tissues
of high turnover: the hematopoietic system, the gastroin-
testinal tract, and male germ cells.10–13,15 Distinct from
other laboratory strains, CAST/EiJ mice have telomere
length and distribution that mimic those of humans
(average telomere length ~15 kb).16 We have previously
shown that, similar to dyskeratosis congenita patients,
CAST/EiJ mTRþ/mice are haploinsufﬁcient for telomerase
and develop end organ defects when telomeres are
short.15,17 Wild-type littermates of late-generation hetero-
zygous mice also inherit short telomeres.15 However,
whether these short telomeres can cause clinically relevant
phenotypes that resemble those of aging is not known.
Here, we show that mice that are otherwise wild-type at
the telomerase locus but have short telomeres develop
degenerative defects in both hematopoietic and immune
systems. These defects mimic the hematopoietic and
immunosenescence phenotypes present in dyskeratosis
congenita patients. Our ﬁndings suggest that the short-
telomere genotype (telotype)18 is a unique heritable trait,
sufﬁcient to mediate degenerative disease even when
telomerase is wild-type.1Department of Oncology, 2Department of Molecular & Comparative Pathobiology, 3Department of Molecular Biology & Genetics, 4Graduate Program in
Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
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Figure 1. Hematopoiesis Is Ineffective in Wild-Type Mice with Short Telomeres
(A) Scheme and nomenclature of mTRþ/ breeding. HG7 refers to the seventh heterozygous generation, and wt8*1 refers to the ﬁrst
generation born from HG7 crosses.
(B–F) Frequency distribution of telomere lengths as measured by qFISH shows that wt* mice have shorter telomeres than wild-type mice
(average wild-type ¼ 50,000 telomere ﬂuorescence units [TFU], wt* ¼ 39,000 TFU; p < 0.0001; n ¼ 3 per group). wt* mice have low824 The American Journal of Human Genetics 85, 823–832, December 11, 2009
Material and Methods
Mice were housed on the Johns Hopkins University School of
Medicine campus, and all procedures were approved by its Institu-
tional Animal Care and Use Committee. Blood counts and dif-
ferentials were performed in a clinical lab with the use of standard
antibodies: anti-Annexin V, B220, CD3, CD4, CD8, CD48, CD150,
and c-kit (Becton Dickinson). Flow cytometry was performed on
a FACS Calibur with the use of standard antibodies (Becton Dick-
inson). Quantitative ﬂuorescence in situ hybridization (qFISH)
and 5-ﬂuorouracil studies were performed as described previ-
ously.19 IgM quantitation was performed via standard ELISA
(Bethyl Laboratories). Mice were immunized with TNP-Ficoll
(10 mg, Biosearch Technologies) and Imject Alum (Pierce) similarly
to themethods described inMorra et al.19We quantitated antigen-
speciﬁc IgM 3 days prior to immunization and on day 7 after using
ELISA (TNP-OVA, Biosearch Technologies) as described previ-
ously.19 T cell isolation was performed with EasySep (StemCell
Technologies). T cells were stimulated with CD3 5 mg/mL (plate-
bound) and CD28 10 ng/mL (eBioscience). Cells were plated at
1.5 3 106 per mL. MTT assay was performed in accordance with
the manufacturer’s instructions (Roche). EdU detection was per-
formed 16 hr after incubation (Invitrogen). Tissues were prepared
and ﬁxed as described previously,15 and all pathologic analyses
were performed blinded to genotype. Statistical analyses were per-
formed with Prism software for Windows. Means were compared
with Student’s t test, and all p values shown are two-sided.
Results
Short Telomeres Are Inherited in wt* Mice
To examine the consequences of short telomeres when
telomerase is wild-type, we bred CAST/EiJ mTRþ/ mice
successively.15 We bred mTRþ/ mice to each other and
assigned the generation number. For example, ﬁrst-hetero-
zygous-generation mTRþ/mice were termed HG1, second
heterozygous generation as HG2, etc. To distinguish wild-
type progeny from these crosses, we termed them wt* and
indicated the generation number. For example, wild-type
mice born of mTRþ/ HG7 were named wt8*1 (Figure 1A).
As previously shown,15 wt* mice inherit the short telo-
meres and thus have a shorter telotype than wild-types
(Figure 1B). With these short telomeres, wt* mice provide
an opportunity to understand the contribution of short
telomeres to human aging.
wt* Mice Have Hematopoietic Defects
Haploinsufﬁciency for telomerase components leads to
aplastic anemia, and mTRþ/ mice with short telomeres
have low blood counts.15 Hematopoietic function also
declines with age and manifests as progressive cytopenias,The Americaa decrease in hematopoietic organ cellularity, and a
decreasing tolerance to cumulative doses of chemo-
therapy.20–22 To determine whether short telomeres are
sufﬁcient to mediate these defects, we examined blood
counts. wt* mice developed low absolute neutrophil and
platelet counts (Figures 1C and 1D). These cytopenias
were associated with a decrease in bonemarrow and spleen
cellularity, consistent with a defect in bone marrow
production (Figures 1E and 1F). When we challenged wt*
mice with 5-ﬂuorouracil, they had a more profound nadir
and lower leukocyte counts at the time of expected
recovery, though these defects were more profound in
mTRþ/ littermates (Figure 1G). The delay in recovery of
white cell count after chemotherapy is consistent with
a defect in bone marrow progenitor pools. Thus, even
when telomerase is wild-type, the short telotype leads to
a degenerative bone marrow failure syndrome.
Hematopoietic Progenitor Defects in Wild-Type Mice
with Short Telomeres
Although stem cell function declines with age, in certain
mouse strains the frequency of hematopoietic stem cells
increases with age.23 To examine whether wt* mice have
an increase in stem cell number, we assayed the frequency
of SLAM cells.24,25 Consistent with their progenitor
phenotype, SLAM cells in CAST/EiJ mice express the c-kit
antigen and are enriched by depleting committed lineages
(Figure S1).24 We also found that the frequency of SLAM
cells increased in aging CAST/EiJ mice, similar to what
has been described for other strains (Figure 1H).23 To
examine whether young wt* mice develop an age-related
phenotype in the hematopoietic stem cell compartment,
we quantitated the frequency of CD150þCD48c-kitþ cells
and found that they had a nearly 2-fold increase in
comparison to age-matched wild-types (Figure 1H). There-
fore, although hematopoiesis is impaired in wt* mice, the
pool of hematopoietic stem cells increases, suggesting that
these cells may have defects in proliferative expansion.
wt* Mice Develop Lymphocyte Defects that Mirror
Immunosenescence
Lymphocyte function declines with age in humans, and
cells rely on self-renewal and proliferative potential to
maintain antigen speciﬁcity throughout adult life. To test
whether short telomeres can mediate immunosenescence,
we examined lymphocyte compartments. wt* mice had
a profound peripheral B cell lymphopenia that led to
a signiﬁcant decrease in IgM production (Figures 2A and
2B). When challenged with immunization, wt* mice
failed to mount a robust immune response after antigenperipheral-blood absolute neutrophil (C) and platelet counts (D). These cytopenias are associated with a hypocellular bone marrow (D)
and atrophic spleen (F). (E) Peripheral white blood cell count after 5-ﬂuorouracil injection on day 0 shows that both wt* and mTRþ/
mice with short telomeres have lower nadir and lower day 12 white counts as compared with wild-type mice.
(G) Percentage of bone marrow cells identiﬁed by SLAM markers (CD150 and CD48) that are c-kitþ. Young mice with short telomeres
(2 mo), including wt* mice, have increased frequency of SLAM-c-kitþ cells as compared with age-matched wild-type mice. This increase
is similar to the expansion of this compartment in older wild-typemice (12mo).Micewere examined at 2mo of age, and each experiment
included at least ﬁve mice per genotype. p values < 0.05 are indicated by *, < 0.01 by **. Error bars represent standard error of the mean.n Journal of Human Genetics 85, 823–832, December 11, 2009 825
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Figure 2. wt* Mice Have Lymphocyte Defects that Mirror Immunosenescence
(A and B) Absolute B cell lymphopenia in the spleen (A) is associated with low serum IgM levels (B).
(C) Fold increase over baseline in antigen-speciﬁc IgM 1wk after immunization. Baseline IgM levels weremeasured in eachmouse 3 days
prior to injection.
(D and E) Absolute T cell lymphopenia in splenocytes is skewed and favors loss of CD4 cells (D), as shown by the decrease in CD4/CD8
ratio (E).
(F–J) T cells fromwt* andmTRþ/mice with short telomeres fail to expand after CD3-CD28 stimulation, as quantitated by theMTTassay
(F). This failure to expand is associated with an increase in the proportion of Annexin-V-positive apoptotic cells (G), as well as a decrease
in the proportion of live cells in S-phase (I). Representative ﬂow cytometry plots for the quantitation shown in (G) and (I) are show in
(H) and (J), respectively. Mice were examined at 3–6 mo of age.exposure (Figure 2C). mTRþ/ mice with short telomeres
also developed similar defects, consistent with observa-
tions in dyskeratosis congenita patients who have defects
in antibody production and humoral immunity (Figures826 The American Journal of Human Genetics 85, 823–832, Decemb2A–2C).26 T cell function also declines with age, and CD4
lymphopenia in the presence of an intact CD8 count is
characteristic of immunosenescence.27We therefore exam-
ined T cell numbers in wt* mice and found that shorter 11, 2009
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Figure 3. The Short Telotype Predicts
Survival
(A) Kaplan-Meier survival plot of mTR/
mice that died prematurely. Median
survival for wild-type, KOG2, and KOG10
mice was 476, 212, and 51 days, respec-
tively (p < 0.0001 for both compared to
wild-type; log-rank test).
(B) Median survival of mTR/mice is pre-
dicted by the generation number, a surro-
gate for telomere length with R2 as shown
(p < 0.0001, Pearson’s test).
(C) Survival plot of heterozygousmice that
died prematurely. Median survival was
464, 292, 175, and 108 days for HG7–
HG10 mice, respectively (p ¼ 0.6, 0.006,
and 0.003 for HG8, HG9, and HG10
compared with HG7, respectively; log-
rank test).
(D) Mendelian ratio of mTR/ pups from
mTRþ/ parents in successive generations
(total n ¼ 3091 pups examined). By the
tenth generation of breeding, 9% of pups
had the mTR/ genotype, in comparison
to an expected 25% (p ¼ 0.004; chi-square
test).telomeres led to a general T cell lymphopenia (Figure 2D).
Speciﬁcally, wt* mice developed an asymmetric lympho-
penia with a more severe deﬁcit in CD4 cells in compar-
ison to CD8 cells (Figure 2E). mTRþ/ mice with short
telomeres developed similar patterns of preferential CD4
lymphopenia. This is noteworthy given the predilection
of dyskeratosis congenita patients to an opportunistic
infection spectrum similar to that of patients with the
acquired immunodeﬁciency syndrome (e.g., Pneumocystis
carinii).28,29 Therefore, short telomeres in wt* mice are
sufﬁcient to cause features of the combined immunodeﬁ-
ciency associated with aging. These ﬁndings are particu-
larly signiﬁcant given the association of short telomeres
with an increased mortality due to infection in elderly
individuals,30 and they suggest that short telomeres can
directly mediate an immunodeﬁcient state.
wt* Mice Have Proliferative Defects in T Lymphocytes
To determine whether short telomeres can cause qualita-
tive T cell defects when telomerase is wild-type, we isolated
and stimulated T cells. T cell activation and proliferation
are known to be associated with a burst in telomerase
activity that sustains clonal expansion after antigen stimu-
lation.11,31,32We therefore reasoned that wild-type telome-
rase may sustain the proliferative capacity of T cells even
when telomeres are short. When we stimulated wt*
T cells in vitro, they failed to expand in comparison to cells
from true wild-types, and in fact responded similarly to
those of mTRþ/ mice (Figure 2F). To examine the under-
lying mechanism, we assayed for apoptosis, and we found
that although there were no baseline differences (not
shown), wt* T cells had an increase in the apoptotic frac-
tion after stimulation in comparison to wild-type cells
(Figures 2G and 2H). Because short telomeres also impairThe Americancell-cycle progression,33 we examined cell-cycle proﬁles.
We found that wt* T cells had fewer cells in S-phase in
comparison to wild-type cells (Figures 2I and 2J). This
was associated with an accumulation at G2-M, a check-
point that is well characterized in response to telomere
shortening.33–35 These defects were all more prominent
in mTRþ/ mice. Thus, when telomeres are short, T cell
proliferation cannot be sustained and short telomeres
cause qualitative defects by inducing both apoptosis and
impaired cell-cycle progression, even when telomerase is
wild-type.
Clinical Consequences of Bone Marrow Failure
in Mice with Short Telomeres
To examine the clinical consequences of short telomeres,
we examined survival. mTR/ mice showed progressive
worsening of a survival defect with each generation, similar
to what was previously shown (Figure 3A).15 In fact, the
generation number, a surrogate for telomere length, could
precisely predict the median survival of mTR/mice (R2¼
0.95, p< 0.0001) (Figure 3B). Late generation mTRþ/mice
also had an increased incidence of premature death. In
these mice, similar to mTR/mice, the survival defect dis-
played genetic anticipation (Figure 3C). Consistent with
a pattern of anticipation, the Mendelian ratio of mTR/
pups from late-generation mTRþ/ parents decreased
successively. By the tenth generation of heterozygous
breeding, only 9% of pups had the mTR/ genotype,
compared with an expected 25% (p ¼ 0.004, chi-square
test). We also examined whether wt* mice had a survival
defect and were able to document several premature deaths
in the ﬁrst 6 mo of life. However, these trends have not
reached statistical signiﬁcance and need to be veriﬁed in
ongoing long-term prospective studies. Together our dataJournal of Human Genetics 85, 823–832, December 11, 2009 827
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Figure 4. Histopathology Identifies
Mucosal Defects and BoneMarrow Failure
as the Cause of Death in Mice with Short
Telomeres
(A) Photomicrographs of spleen histology
in wild-type and mTR/ mice showing
effacement of the normal white-red pulp
architecture and replacement with
myelo-erythropoiesis as evidenced by the
presence of megakaryocytes (arrows) in
the inlet at 200X.
(B) Representative photomicrograph of
typhlocolitis lesion seen in mTR/ mice.
Compared to wild-type mice (left panel),
the lamina propria and submucosa is
inﬁltrated by neutrophils in the cecum,
indicating an ongoing infection (right).
There was evidence of colitis in 100% of
mTR/ mice examined (8 of 8).
(C) Micrographs from mid-intestine
showing gastrointestinal mucosal defects
in wt* mice. Compared with wild-type
mice, in which no abnormalities were
ever seen (0 of 9), wt* mice had evidence
of villous blunting (3 of 6). In mTRþ/ and mTR/ mice with short telomeres, more-severe defects were noted, including severe villar
blunting adjacent to areas of crypt hyperplasia, as well as regions of complete villous atrophy and crypt loss, which were present in all
mTR/ mice examined, as illustrated.indicate that, at least when mice are null or haploinsufﬁ-
cient for telomerase, short telomeres can predict the onset
of a fatal illness.
Short Telomeres Do Not Promote Tumorigenesis on
the CAST/EiJ Background
Short telomeres have been implicated in genomic insta-
bility and in promoting tumorigenesis.12,36 To examine
whether mice with short telomeres on the CAST/EiJ back-
ground have an increased incidence of tumors, we
performed careful necropsies. As previously shown,15
mTR/mice hadmicroadenomas in the lower gastrointes-
tinal tract. However, these small lesions were localized to
the mucosa and did not invade the basement membrane.
Microadenomas were notably absent in wt* and mTRþ/
mice up to the tenth generation. Furthermore, we did
not detect any evidence of gross or microscopic malig-
nancy in early- or late-generation mTR/, mTRþ/, and
wt* mice that we examined (50 mice per group). To deter-
mine whether short telomeres cause genomic instability,
we examined metaphases prepared from primary cells
from CAST/EiJ mice with short telomeres. We also did
not detect spontaneous chromosome fusions in any of
the three groups of mice (n ¼ 20 mice per group, 20 meta-
phases per mouse). Together, these data indicate that in the
presence of an intact DNA damage response, and in the
CAST/EiJ strain that possesses a human telomere length
and distribution, the most prominent clinical conse-
quences of short telomeres manifest as degenerative
disease.
Bone Marrow Failure as the Primary Cause of Death
Humans with short telomeres have an 8-fold increased risk
of mortality due to infection, and wt* mice share with828 The American Journal of Human Genetics 85, 823–832, DecembmTRþ/ and mTR/ mice all of the hematopoietic and
immune defects, albeit less severely. To examine the cause
of death in these mice, we performed careful histopa-
thology. Two features consistently distinguished mTR/
and mTRþ/ mice from wild-type mice. Mice with short
telomeres had evidence of severe extramedulllary hemato-
poiesis (0 of 9 wild-type, 5 of 5 mTR/, and 4 of 5 mTRþ/
mice; p ¼ 0.01 and p ¼ 0.02, respectively, as compared to
wild-type; chi-square test) (Figure 4A). Extramedullary
hematopoiesis is a compensatory response to bonemarrow
failure. Additionally, mTR/ and mTRþ/ mice had
evidence of necrotizing typhlocolitis, an infection that is
usually superimposed on areas of mucosal atrophy (Fig-
ure 4B). Typhlocolitis is a superinfection of the gastrointes-
tinal tract that leads to microperforartion and death from
bacteremia.37 Typhlocolitis has been best described in
the setting of bone marrow suppression and mucosal
injury after chemotherapy, as well as in aplastic anemia.37
mTR/ andmTRþ/mice have knownmucosal atrophy,15
and wt* mice also had mucosal blunting and villous short-
ening (0 of 9 wild-types, 3 of 6 wt9*1; p ¼ 0.02; chi-square
test) (Figure 4C). Wt* mice also had evidence of enteritis
and extramedullary hematopoiesis, though these defects
were less severe than those in null mice. Our analyses
suggest that the primary cause of death in mice with short
telomeres is opportunistic infection due to typhlocolitis,
related to impaired bone marrow function and superim-
posed on mucosal defects in the gastrointestinal tract.
Telomerase Dose Is Limiting in Development
The fact that ﬁrst-generation wt* mice have short telo-
meres implies that when telomerase is haploinsufﬁcient,
telomere-length equilibrium cannot be established after
one generation.15 To examine whether wild-type telomereer 11, 2009
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Figure 5. Wild-Type Telomerase Elongates Telomeres Incrementally across Generations; Example of mTRþ/ HG4 Family Is Shown
(A) Breeding scheme of wt* mice with nomenclature.
(B–D) Frequency distribution of telomere length as examined by qFISH on metaphase splenocytes for each wt* generation, compared
with true wild-types, are shown in each panel (n ¼ 2 mice per group). Degenerative phenotypes resolve with successive telomere elon-
gation, as shown by an increase in testes weight (C) and the decreasing frequency of aberrant tubules in (D). The number of examined
mice is shown below each column, and testes weight was corrected for body weight. Mice were examined at 12 mo of age.length could be reestablished and to determine the rate of
telomere elongation when telomerase is wild-type, we bred
wt* mice to each other in two independent lines (Figure 5A
and Figure S2A). Although telomerase elongated the short-
est telomeres, it surprisingly did so only incrementally
across each generation (Figure 5B and Figure S2B). In fact,
telomere-length analysis showed that it took as many
generations for telomeres to return to wild-type length as
it took for them to shorten in heterozygous breeding. For
example, wt5*1 telomeres were approaching wild-type
lengths after four generations of breeding (Figure 5B).
Although the degenerative phenotype became less severe
with successive generations of wt* breeding, in one line,The Americaneven two generations later, there was evidence of organ
dysfunction that was never seen in wild-type mice (Figures
5C and 5D and Figures S2C and S2D). These data indicate
that although wild-type telomere lengths can eventually
be reestablished, telomerase levels are tightly regulated in
development and lead to incremental elongation across
each generation.
Discussion
The phenotypes that we identify in wt* mice provide
a model for understanding the role of short telomeres in
human aging. In the hematopoietic and immune systems,Journal of Human Genetics 85, 823–832, December 11, 2009 829
short telomeres are sufﬁcient to induce the age-associated
degenerative changes that resemble those seen in dyskera-
tosis congenita. The presence of defects in tissues of high
turnover indicates that short telomeres impair stem cell
and lymphocyte proliferation even when the genes for
telomerase are wild-type. Although telomerase activity is
enriched in these compartments, this enrichment does
not render to them an indeﬁnite functional capacity. The
clinical signiﬁcance of the bone marrow defects that we
identify is highlighted by the fact that short telomeres
provoke a life-threatening illness in mTRþ/ and mTR/
mice and may also contribute to a survival defect in wt*
mice. Short telomeres have been associated with prema-
ture death due to infection in elderly individuals,30 and
our data indicate that short telomeres alone are sufﬁcient
to mediate the immunodeﬁciency of aging and probably
its consequent morbidities.
We did not identify an increased incidence of tumors in
CAST/EiJ mice with short telomeres. Aside from noninva-
sive microadenomas which were present in mTR/
mice, we did not observe any evidence of a neoplastic
process in mTR null, heterozygous, or wt* mice. Addition-
ally, we did not observe any evidence of genomic insta-
bility. Our data are in contrast to prior studies in the
C57BL/6 background, which noted an increase in sponta-
neous tumors in mTR/ mice.12,36 They indicate that, on
the Castaneus genetic background, which possesses
human telomere dynamics, and in the presence of an
intact DNA damage response, short telomeres primarily
mediate degenerative organ failure. Our observations are
consistent with several studies in tumor-prone mouse
models that have demonstrated that short telomeres are
indeed protective and play a powerful tumor-suppressor
role.38–43 Also, in dyskeratosis congenita, the primary
cause of mortality in more than 90% of cases is organ
failure.44 Although dyskeratosis congenita patients do
have an increased incidence of cancer,45 the predominant
phenotype is degenerative, and cancer-related mortality is
less common. Collectively, this evidence suggests that
short telomeres have their most prominent clinical conse-
quences in degenerative phenotypes that lead to organ
failure. The molecular mechanisms by which short telo-
meres may, rarely, be associated with an increase in tumor
incidence remain to be fully elucidated.
Finally, our data indicate that telomere length is a unique
heritable trait. Because telomerase levels are tightly regu-
lated in development, parental telomere length partly
determines telomere-length heterogeneity across popula-
tions.46 Supporting these observations, in some human
families that carry mutant telomerase genes, wild-type
progeny also have short telomeres in comparison to those
of age-matched controls.47 The fact that telomerase dose is
limiting across generations may have particular signiﬁ-
cance for attempts to use adult somatic cells, which may
have short telomeres, in stem-cell-based applications. In
this setting, short telomeres could theoretically limit the
long-term viability of these cells, even when telomerase830 The American Journal of Human Genetics 85, 823–832, Decembdose is restored. Given that the spectrum of telomere-
mediated disease is broad and includes idiopathic
pulmonary ﬁbrosis as well as cryptogenic forms of liver
cirrhosis,48–50 our data implicate the short telotype as sufﬁ-
cient to induce features of dyskeratosis congenita in other-
wise wild-type individuals.
Supplemental Data
Supplemental Data include two ﬁgures and can be found with this
article online at http://www.cell.com/AJHG.
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